|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.54 CNY | -0.28% |
|
-5.99% | -16.94% |
EPS & Dividend: Gan & Lee Pharmaceuticals.
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | 0.2 | 1 | 1 | 0.24 | 0.28 | 0.34 |
| Rate of return | - | - | 0.38% | 2.27% | 1.47% | 0.42% | 0.5% | 0.6% |
| EPS 2 | 2.59 | -0.78 | 0.6 | 1.04 | 1.93 | 2.285 | 2.67 | 3.15 |
| Distribution rate | - | - | 33.3% | 96.2% | 51.8% | 10.5% | 10.5% | 10.8% |
| Reference price 2 | 70.34 | 32.58 | 52.65 | 44.10 | 68.07 | 56.54 | 56.54 | 56.54 |
| Nbr of stocks (in thousands) | 561,540 | 565,653 | 590,049 | 597,089 | 595,202 | 595,202 | - | - |
| Announcement Date | 27/04/22 | 30/03/23 | 24/04/24 | 24/04/25 | 22/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
Past dividends: Gan & Lee Pharmaceuticals.
| 11/06/2025 | Ex-dividend date - 1 CNY | 05:00 |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
| 0.42% | 0.5% | 24.74x | - | 6.39x | ||
| 0.56% | 0.63% | 18.08x | 2.1x | 3.98x | ||
| 0.62% | 0.63% | 25.71x | 3.74x | 5.16x | ||
| -.--% | 0.03% | 34.46x | 7.05x | 11.78x | ||
| 4.1% | 4.26% | -126.06x | 2x | 2.76x | ||
| -.--% | -.--% | 31.15x | 1.43x | 3.41x | ||
| -.--% | -.--% | -5.67x | 3.45x | 7.62x | ||
| -.--% | -.--% | 14.44x | 2.82x | 2.49x | ||
| -.--% | 0.06% | 48.03x | 5.37x | 6x | ||
| -.--% | -.--% | 24.28x | 3.46x | 5.11x | ||
| Average | 0.57% | 0.61% | 8.92x | 3.49x | 5.47x | |
| Weighted average by Cap. | 0.7% | 0.74% | 7.47x | 3.43x | 5.46x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















